{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:54:01Z","timestamp":1784879641820,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000298","name":"National Association for Colitis and Crohn's Disease","doi-asserted-by":"publisher","award":["U01 AG016976"],"award-info":[{"award-number":["U01 AG016976"]}],"id":[{"id":"10.13039\/501100000298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;D Transl Res &amp; Clin Interv"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Are reductions in the rate of decline from the new disease\u2010modifying treatments (DMTs) in early Alzheimer's disease (AD) meaningful? We examined whether such reductions may be reflected in changes in health\u2010related resource use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with Clinical Dementia Rating (CDR) = 0.5 or 1 with a clinical diagnosis of mild cognitive impairment or AD, reflecting clinical trial populations. Health\u2010related resource use was reported using the Resource Use Inventory (RUI) including direct medical care, non\u2010medical care, unpaid informal care, and time use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Faster decline in CDR\u2013Sum of Boxes (CDR\u2010SB) from baseline was independently associated with higher likelihood and hours of informal care received, and lower likelihood of employment\/volunteer work, but not with direct medical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Reductions in the rate of decline in CDR\u2010SB seen from DMTs significantly affect patients\u2019 work capacity and need for informal care, indicators of economic impact meaningful to patients, families, and health systems. These measures are not readily captured in administrative data sets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Following a cohort of participants with MCI or mild dementia due to AD that mimics participants targeted for AD trials, this study showed slower decline in CDR\u2010SB have significant effects on patients\u2019 work capacity and need for informal care, but not on their direct medical care utilization such as hospitalizations, ED use, and doctors\u2019 visits.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Capturing potential benefits in health\u2010related resource use may require direct measures of informal care and work\/volunteer effort which are meaningful outcomes to patients, families and health systems.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Caution is needed in our effort to assess benefits of recently developed disease modifying treatment in AD using electronic health records and administrative data from which utilization of direct medical care are routinely collected as these data sources may not capture the most apparent changes in resource utilization during early disease stages.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.12455","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:20:22Z","timestamp":1722410422000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Meaningful benefit of disease\u2010modifying treatment: Evaluating changes in health\u2010related resource use"],"prefix":"10.1002","volume":"10","author":[{"given":"Carolyn W.","family":"Zhu","sequence":"first","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine Icahn School of Medicine at Mount Sinai  New York New York USA"},{"name":"James J. Peters VA Medical Center  Bronx New York USA"},{"name":"Alzheimer's Disease Research Center Department of Psychiatry Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sano","sequence":"additional","affiliation":[{"name":"James J. Peters VA Medical Center  Bronx New York USA"},{"name":"Alzheimer's Disease Research Center Department of Psychiatry Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. July 6 2023. Accessed July 21 2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200127"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010022\u201000984\u2010y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010190426"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.06.008"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010191212"},{"key":"e_1_2_9_10_1","unstructured":"Special Committee on Aging United States Senate. America's Aging Workforce: Opportunities and Challenges(December 2017)."},{"issue":"3","key":"e_1_2_9_11_1","first-page":"S191","article-title":"ADCS prevention instrument project: pharmacoeconomics: assessing health\u2010related resource use among healthy elderly","volume":"20","author":"Sano M","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318142774e"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000213865.09806.92"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/37.3.323"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022\u20103956(82)90033\u20104"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532\u20105415.2005.53461.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.10.017"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010publhealth\u2010040617\u2010013517"},{"key":"e_1_2_9_24_1","unstructured":"Stata Statistical Software: Release 17. College Station TX. StataCorp LLC.2021. America's Aging Workforce: Opportunities and Challenges."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00003"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00005"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010220303"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12430"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.12455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:44:43Z","timestamp":1761493483000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.12455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/trc2.12455"],"URL":"https:\/\/doi.org\/10.1002\/trc2.12455","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2023-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12455"}}